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Introduction 
Bone is susceptible to a range of diseases, like other tissues.  However, it is generally difficult to 
deliver and retain drugs in the bone.  Bone is composed unique materials such as the inorganic 
compound hydroxyapatite (HAP) and bone-matrix proteins, which are quite different from the 
components of other tissues.  Among them, HAP may be a promising target for selective drug 
delivery to bone. 
 Now, two promising methods have been reported for selective drug delivery to the bone as 
a target HAP.  One is a class of molecules known as bisphosphonates.  Systemic administration of 
bisphosphonates commonly results in 20-50% deposition of the molecule at bone tissues, with 
minimal accumulation at other sites [1].  These compounds not only show anti-osteoporosis effect 
by themselves [2] but are useful as the drug delivery carrier to the bone [3-6].  Another is the 
oligopeptide having high affinity to the bone, described in this review. 
The structures of several bone non-collagenous proteins that bind to HAP have a repeating 
sequence of acidic amino acids (Asp, Glu), which may serve as a HAP binding site.  Osteopontin 
and bone sialoprotein, two major non-collagenous proteins in bone, have L-Asp and L-Glu 
repetitive sequences, respectively (Fig. 1), and rapidly bind to HAP after they are secreted in 
osteoblastic cell culture [7-9].  Thus, these acidic oligopeptides are candidate bone-targeting 
carriers.  It was hypothesized that, after systemic administration, a drug tagged with such an 
oligopeptide would be selectively delivered and bind to bone, where the active drug would be 
released gradually during bone remodeling processes. 
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This review describes the properties of acidic oligopeptides and introduces the tagging of 
three model drugs, estradiol, quinolone antibiotics, and tissue-non-specific alkaline phosphatase 
(TNSALP), with an acidic oligopeptide to examine the clinical feasibility of the acidic 
oligopeptide strategy for selective drug delivery to bone. 
 
Bioproperties of acidic oligopeptides 
Homo-oligopeptides consisting of two to ten acidic amino acid residues, conjugated with 
9-fluorenylmethylchloroformate (Fmoc) or fluorescein (FITC), were synthesized by routine 
solid-phase methods (Fig. 2).  The dissociation constant (Kd) decreased with increasing numbers 
of acidic amino acid residues, and the binding rate (Bmax) reached almost maximum at a length of 
six residues.  The affinity for HAP was not related to the optical isomeric form (L or D) or the 
acidic amino acid species (Asp or Glu) [10].  When intravenously administered, 
fluorescein-labeled L-Asp hexapeptide (FITC-D6) disappeared from the plasma with a biological 
half-life of 60 min, and 95% of the administered FITC was excreted within 24 h, but FITC-D6 
rapidly bound and retained on the bone and teeth (Fig. 3) and was detectable in bone tissues even at 
14 d after administration, but it was undetectable in other tissues [11].  Among the isomeric forms 
of the amino acids, the retention time was much longer for D-amino acid oligopeptides than for 
L-peptides.  However, the L-amino acid (Asp) hexapeptide was chosen, because the D-peptide 
may be insensitive to hydrolysis in bone thus would not release the tagged drug. 
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Oligopeptide-tagged estradiol for osteoporosis 
Osteoporosis is a serious problem for postmenopausal and aged women, and estrogen 
deficiency plays a causative role in its development.  Estrogen can act directly or indirectly on 
osteoblasts and osteoclasts through estrogen receptor-mediated mechanisms [12-16], resulting in 
an anabolic effect on bone formation in estrogen-deficient animal models [17, 18].  Estrogen 
replacement therapy is an effective treatment in postmenopausal women to prevent reduction of 
bone mineral density [19].  However, systemically administered estrogen is widely distributed to 
tissues other than bone, and prolonged therapy may increase the risks of endometritis, breast and 
endometrial cancer, and intrauterine hemorrhage [20, 21]. The development of osteoporosis 
therapies that are more efficient and selective for bone is desirable to avoid such adverse reactions. 
Estradiol (E2) was tagged with the L-Asp hexapeptide at the 3-position (E2-3D6) or the 
17β-position (E2-17βD6) via a succinate ester (Fig. 4), and the pharmacokinetics and 
anti-osteoporotic effects of these compounds were examined [10, 22].  First, the binding affinities 
of these compounds at human estrogen receptors, ERα and ERβ, were tested in vitro.  The 
affinities of E2-3D6 and E2-17βD6 to both estrogen receptors were about 100-fold and 10,000-fold, 
respectively, less than those of estradiol.  Moreover, it is unlikely that the tagged estradiols can 
permeate through the plasma membrane, because of their hydrophilicity and large molecular size, 
and it seems probable that hydrolysis of the ester bond between estradiol and the L-Asp 
hexapeptide portion would be required for the tagged estradiols to show biological activity.  At 6 h 
after a single intravenous administration (3.7 μmol/kg), the apparent tissue-to-plasma 
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concentration ratio of the tagged estradiols was almost 1.0 in most tissues and organs, indicating 
that these compound could not distribute or accumulate in tissues.  Among the tissues examined, 
untagged estradiol was most highly distributed in the uterus, where it might cause adverse effects 
such as endometritis, whereas the accumulation of the tagged estradiols in the uterus was clearly 
lower.  On the other hand, tagged estradiol was distributed to bone at 50-fold the level of untagged 
estradiol.  Moreover, the level of tagged estradiol in bone decreased very slowly, falling to basal 
level (10.5 ± 3.3 pmol/g) by 7 days, whereas untagged estradiol declined to the basal range within 
1 day after injection. 
It is well known that estradiol with a mono- or di-ester at position 3 or/and 17 shows 
prolonged estrogenic effects in the body due to the biological stability of esterified estradiol [23, 
24].  This is so because removal of the ester is necessary for further metabolism and excretion of 
estradiol, and the de-esterification step appears to be the rate-limiting process in the elimination 
[25].  Indeed, at 6 h after the injection of untagged estradiol, the plasma concentration of estradiol 
had decreased almost to the basal level (7.6 ± 1.9 pmol/mL), whereas the tagged estradiols 
remained in the circulation at 6 h (E2-3D6; 26.7 ± 9.0 pmol/mL, E2-17βD6; 22.0 ± 12.0 pmol/mL, 
respectively).  The lower total body clearance (CLtot) of the tagged estradiols, compared with that 
of untagged estradiol, may result from superior biological stability.  This would be favorable for 
the long-term action of tagged estradiol in bone. 
When tagged estradiol (0.11, 0.37, or 1.1 μmol/kg, every seventh day) or untagged 
estradiol (0.37 μmol/kg, every third day) was intravenously administered into ovariectomized 
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(OVX) mice for 28 days, the tagged estradiol dose-dependently reversed the decreased bone 
mineral density (BMD), and the estrogenic effects were selective to bone.  The untagged estradiol 
increased not only the BMD but also the weights of the uterus and liver [10, 22].  Estradiol caused 
hypertrophy of uterine tissues and fatty degeneration in the liver.  These results indicate that tagged 
estradiol reduced the risk of systemic adverse effects of estradiol, while retaining the osteogenic 
effect in bone.  
The retention of E2-3D6 in the blood circulation and bone and its anti-osteoporotic effects 
were greater than those of E2-17βD6 [10,22].  The difference may be attributable to the greater 
stability of E2-3D6 to hydrolysis, compared with E2-17βD6, so that the retention in bone is longer 
for E2-3D6 than for E2-17βD6.  It is likely that the tagged estradiols bound to bone are gradually 
hydrolyzed on the bone surface, possibly by peptidases, acid secreted by osteoclasts, and/or 
non-specific esterases, and that the released estradiol then acts via estrogen receptors. 
Thus, these acidic oligopeptide-tagged estradiols, E2-3D6 and E2-17βD6, are promising 
candidates for the treatment of postmenopausal osteoporosis.  The prolonged effect and selective 
delivery to bone should extend the medication interval and reduce the adverse effects of estradiol.  
However, when considering the clinical use of these oligopeptide-tagged estradiols, intravenous 
injection is undesirable because of the potential for poor compliance.  The bioavailability of 
E2-17βD6 after oral administration was less than 10%.  Therefore, Yokogawa et al. have developed 
an intranasal preparation to increase the bioavailability of the tagged molecules [26].  The 
bioavailability of E2-17βD6 after intranasal administration was increased to 75% by incorporating 
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2,6-di-O-methyl-β-cyclodextrin into the formulation, thereby creating an inclusion complex with 
E2-17βD6 that could achieve prolonged residence in the nasal cavity. The acidic 
oligopeptide-tagged estrogen provided increased medication compliance because of its 
long-acting and easy administration, and it increased anti-osteoporotic efficacy because of 
selective delivery to bone and reduced adverse effects of estradiol, resulting in improved quality of 
life for patients. 
 
Oligopeptide-tagged quinolone antibiotics for osteomyelitis 
Osteomyelitis is a progressive infectious process resulting in inflammatory destruction of bone, 
bone necrosis, and new bone formation.  Chronic osteomyelitis is generally treated with surgical 
debridement, following the administration of parenteral antibiotics such as β-lactams or 
aminoglycosides.  Without adequate debridement, most antibiotic regimens fail, regardless of the 
duration of therapy. Even when all necrotic tissue has been removed, the remaining bed of tissue 
must be considered as contaminated with the responsible pathogens.  Thus, it is recommended to 
treat the patient with antibiotics for at least 4 weeks [27-29].  Moreover, the serum bactericidal titer, 
which is defined as the maximal dilution of the patient’s serum that is able to kill the infecting 
organism in vitro, should be 1:4 or greater for a cure [30].  Thus, high doses and long-term 
administration of antibiotics are required for the treatment of osteomyelitis, because the delivery 
of antibiotics to bone is difficult. As the fluoroquinolones have a broad spectrum of activity in vitro, 
including activity against Gram-negative organisms, Staphylococcus aureus, and S. epidermidis 
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[31], improving their bone distribution should increase their therapeutic effectiveness. 
Takahashi et al. have designed levofloxacin (LVFX) tagged with the L-Asp hexapeptide at 
position 3 in the pyridone carbonic acid moiety, an active center of the drug, via a glycolate ester, 
(LVFX-3D6) and norfloxacin (NFLX) tagged with the L-Asp hexapeptide at position N7 in the 
piperazinyl group via a glycolate and succinate linker (NFLX-7D6)(Fig. 5) [32].  The minimum 
inhibitory concentrations (MIC) for anti-microbial activity of LVFX-3D6 and NFLX-7D6 against S. 
aureus in vitro were 100- and 60-fold less, respectively, than those of the respective untagged 
drugs.  One reason for this may be the increased hydrophilicity, arising from the acidic 
oligopeptide tag.  Fluoroquinolones act by inhibiting bacterial topoisomerase II, which is 
responsible for the replication of double-stranded DNA, and thus must cross the bacterial 
membrane to be effective [33, 34].  The marked reduction of the antimicrobial activity of tagged 
quinolones indicates that the release of the parent drug by hydrolysis was required for biological 
activity, as in the case of tagged estrogen. 
The pharmacokinetic parameters of LVFX-3D6 and NFLX-7D6 after a single intravenous 
injection are shown in Table 1.  The AUC value of each tagged drug was two-fold that of the 
respective parent drug.  In contrast, the Vdss value was significantly less for the tagged drugs than 
for the parent drugs, indicating a low distribution of the tagged compounds into tissues.  The 
biological half-life was not changed by conjugation.  Although these fluoroquinolones themselves 
have some affinity for calcium or bone, the level of tagged drugs in bone was more than 100-fold 
that of the parent drugs for at least 7 days after injection.  After injection of LVFX-3D6, the 
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resulting LVFX was detected in bone marrow at about 1% of the concentration of LVFX-3D6 in 
bone and was continuously released for 7 days. It is known that fluoroquinolones show extensive 
tissue penetration, and as a result, can cause adverse effects in various tissues, including the 
cardiovascular system, central nervous system, skin, liver, musculoskeletal system, and kidneys 
[35, 36].  The risk of adverse events may be decreased by conjugation with an oligopeptide 
because of lower distribution into tissues due to the increased hydrophilicity. 
The therapeutic effect of tagged drugs on osteomyelitis was evaluated using a murine 
model of osteomyelitis, which was prepared by inoculation of S. aureus into the tibia.  The amount 
of S. aureus remaining in the tibia after a single intravenous injection of the drug (27.7 mmol/kg 
for LVFX and LVFX-3D6; 31.3 mmol/kg for NLFX and NFLX-7D6) was determined, but only a 
slight reduction in the number of S. aureus was observed after the administration of LVFX, and no 
effect was seen for NLFX and NFLX-7D6.  The anti-microbial effect of LVFX was temporary, and 
the number of S. aureus had recovered to the level of the untreated control group at 6 days after 
administration.  On the other hand, LVFX-3D6 suppressed the growth of S. aureus for at least 
6 days, showing a prolonged effect. Nevertheless, the effect of LVFX-3D6 was not sufficient to kill 
S. aureus, presumably because the LVFX concentration generated from LVFX-3D6 in the bone 
was insufficient to kill S. aureus.  Fluoroquinolones show a concentration-dependent killing effect 
for susceptible organisms, with higher concentrations of fluoroquinolones resulting in more 
complete killing [37, 38].  Thus, the hydrolytic rate of LVFX-3D6 appears to be an important 
determinant of the maximal anti-microbial effect.  NFLX-7D6 did not release NFLX and did not 
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show any effect.  These findings emphasize the importance of ensuring an appropriate 
susceptibility of the acidic oligopeptide-tagged drug to biological hydrolysis.  To improve the 
effectiveness of the tagged drug, further modification is required, possibly devising a linkage 
susceptible to osteoclast-derived acid, peptidase, or non-specific esterase. 
 
Oligopeptide-tagged enzyme for deficiency of tissue-non-specific alkaline phosphatase 
Hypophosphatasia is an inherited metabolic disorder of defective bone mineralization and is 
caused by a deficiency in tissue-non-specific alkaline phosphatase (TNSALP).  Despite the 
presence of TNSALP in bone, kidney, liver, and adrenal tissue in healthy individuals, clinical 
manifestations in patients with hypophosphatasia are limited to defective skeletal mineralization, 
manifesting as rickets in infants and children and osteomalacia in adults [39].  ALP functions as an 
inorganic pyrophosphatase in bone [40, 41].  Inorganic pyrophosphate (PPi) itself impairs the 
growth of HAP crystals and acts as an inhibitor of mineralization [42-45]. With insufficient 
TNSALP activity, PPi is not adequately hydrolyzed, and the resulting build-up of unhydrolyzed 
PPi in the perivesicular matrix inhibits the proliferation of pre-formed HAP crystals beyond the 
protective confines of matrix vesicle (MV) membranes. 
Hypophosphatasia is caused by the deficiency of a single enzyme, TNSALP, making the 
disorder potentially amenable to enzyme replacement therapy (ERT). However, the results of ERT 
with intravenous infusion of plasma ALP or purified liver ALP in patients with hypophosphatasia 
have been disappointing [46-50].  Recently, one report has suggested that continuous delivery of 
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a high dose of TNSALP to bone would be needed to induce physiological bone mineralization [51]. 
These observations suggest that the ALP enzymes administered intravenously were mostly 
consumed in the visceral organs and thus were not actually delivered to the bone at the 
physiological levels necessary to rescue the lesions.  Therefore, it was tried to develop TNSALP 
targeted to bone by acidic oligopeptide. 
The cDNAs were designed for two enzymes: anchorless recombinant human TNSALP 
(rhTNSALP) and anchorless human TNSALP (about 80 kDa) tagged with a stretch of six L-Asp 
residues at the C terminus (CD6-TNSALP) (Fig. 6) [52].  When these cDNAs were transfected into 
Chinese hamster ovary (CHO-K1) cells, the enzymes were secreted from the cells into the culture 
medium, because they do not have the glycosylphosphatidylinositol anchoring signal peptide 
sequence from the C-terminus of human TNSALP cDNA.  There was no significant difference in 
specific activity, Michaelis constant, or kcat between the two enzymes.  Thus, CD6-TNSALP can 
restore mineralization in hypophosphatasia patients.  Indeed, in cultures of hypophosphatasia 
patient-derived bone marrow cells, the tagged enzyme markedly improved mineralization, similar 
to the untagged enzyme rhTNSALP.  Although PPi completely inhibited the mineralization, even 
in the presence of Pi, the addition of CD6-TNSALP restored the mineralization level to that of the 
PPi-free control culture, as did TNSALP.   Consequently, it seems that both the tagged and 
untagged enzymes may be taken up without modification into osteoblastic cells, possibly by 
endocytosis, and that both show similar bioactivity in terms of mineralization, by degrading PPi in 
the cells. 
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To evaluate the pharmacokinetic tissue distribution of the enzymes, fluorescently labeled 
enzymes were prepared with the Alexa dye.  CD6-TNSALP showed about a 2-4-fold increase in 
bone retention, compared with untagged TNSALP, for at least 7 days after intravenous injection.  
The distribution to other tissues was not significantly different between the two enzymes, although 
the half-lives in the circulation were slightly different (rhTNSALP, 19.1 h; CD6-TNSALP, 14.4 h) 
after a single intravenous injection.  The different half-lives in the circulation may have been due 
to the different carbohydrate structures, i.e., the tagged enzyme was less sialylated than the 
untagged enzyme, based on the result of lectin affinity chromatography [52].  It is known that 
higher sialic acid residue content at the terminus of the carbohydrate chain contributes to a longer 
half-life of ALP in the blood [53, 54]. 
These results suggest the possible clinical application of ERT for hypophosphatasia, 
although further studies are needed to confirm in vivo and clinical effectiveness of the tagged 
enzyme and may encourage us to develop drugs of other large molecule such as growth factors or 
hormones tagged with acidic oligopeptides for some bone diseases and growth disorder. 
 
Bisphosphonates and acidic oligopeptides as bone targeting carrier 
 Fujisaki et al. [3,4] designed a hybrid compound of estradiol and bisphosphonate.  This 
compound was rapidly taken up by bone and increased BMD of OVX rats.  But this hybrid 
compound also increased the uterine weight to have intrinsic hormonal action on estrogen 
receptors, indicating missing in selectivity to the bone.  Many investigators have tried to 
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selectively deliver of several biological active proteins to bone, but none has been successful so far 
in targeting the molecules to the bone and showing that they have the desired biological effect on 
the bone.  Uludag et al. [5,6] have designed aminobisphosphonate conjugated with bovine serum 
albumin and succeeded in delivery the protein to bone with several fold higher concentration and 
longer retention than unconjugated protein.  However, because the cleavage and release the 
bioactive protein from the conjugate may be difficult, it has not been proved until now to exhibit 
the bioactivity on bone after administration of the conjugate of bisphosphonate and some 
biologically active protein or peptide.   
Our small peptide consisting of an acidic amino acid may be more practical as a bone-targeting 
carrier of various drugs for treatment of bone diseases, because it is selectively distributed to the 
bone, where it gradually releases the conjugated drug, whereas it is rapidly degraded and removed 
from plasma [10,11].  On the other hand, a genetically prepared TNSALP tagged with six L-Asp 
oligopeptide at the C terminus accomplished higher accumulation and longer retention in the bone 
than untagged enzyme [52].  Furthermore the tagged enzyme improved mineralization of 
bone-marrow cells from patient of hypophosphatasia, similar to the untagged enzyme [52], 
suggesting the carrier peptide does not influence the enzyme activity, because the molecular size is 
too small compared with the parent enzyme. 
 
Conclusion 
The cumulative results of the studies on acidic oligopeptide conjugation indicate a promising 
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method of selectively delivering drugs to bone.  Owing to the apparently strong affinity of acidic 
oligopeptides for HAP, the targeting system may be widely applicable for both small molecule 
drugs and large molecules as proteins in several bone diseases. 
The presence of an acidic oligopeptide tag altered the drug’s pharmacokinetic and 
biological properties, including blood clearance, distribution to visceral organs, and biological 
activity.  The increased hydrophilicity created by the tag is thought to be responsible for these 
alterations.  In considering clinical use, it is unlikely that tagged molecules would be suitable for 
oral administration because of their high hydrophilicity and their susceptibility to peptidases and 
esterases in the gastrointestinal tract.  Other routes of administration, such as the intranasal route, 
may increase the bioavailability of tagged molecules, and the greater convenience may improve 
compliance and patient quality of life. 
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Acidic amino acids are emphasized.
Fig. 1. Amino acid sequences of bone matrix proteins 















Fig. 3.  Confocal laser scanning microscopic images of bones



























Fig. 4.  Structures of E2-3D6 and E2-17βD6
E2-3D6




















































8.77 ± 0.39 24.8 ± 0.8* 9.66 ± 1.70 20.7 ± 7.8*
Vdss (L/kg) 1.55 ± 0.04 0.27 ± 0.06* 1.86 ± 0.35 0.63 ± 0.14*
t1/2 (h) 0.49 ± 0.09 0.38 ± 0.02 0.52 ± 0.09 0.62 ± 0.17
Table 1.  Pharmacokinetic parameters after an intravenous administration of 
fluoroquinolones and their Asp-oligopeptide tagged drugs 
Each compound was injected into the jugular vein of mice at the indicated dose.
Each value represents the mean ± S.D. (n = 4).
*Significantly different from the parent drug at p < 0.05.
Fig. 6.  DNA constract of CD6-TNSALP
N-signal sequence TNSALP
GPI anchoring signal sequence
(CTTGCTGCAGGCCCCCTGCTGCTCGCTCT
GGCCCTCTACCCCCTGAGCGTCCTGTTC)
Anchor-intact TNSALP
Anchorless CD6-TNSALP
Anchorless TNSALP
Linker
(ACCGGTGAAGCAGAGGCC)
D6
(GACGATGACGACGATGAT)
N-signal sequence TNSALP
N-signal sequence TNSALP
